Engineered T cell therapies
T-knife develops engineered T cell therapies for solid tumors.
Source: LinkedIn company description · Retrieved October 13, 2026
T-knife is a clinical-stage biotechnology company developing engineered T cell and in vivo cell therapies for solid tumors.
T-knife was founded by experts in T cell biology, immunology and cancer immunotherapy, based on research from the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin. The company develops therapies for solid tumors.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
T-knife develops engineered T cell therapies for solid tumors.
Source: LinkedIn company description · Retrieved October 13, 2026
T-knife is advancing two proprietary in vivo cell therapy programs for solid tumors that aim to reprogram immune cells directly within the patient.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 21, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.